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Activation of orexigenic AgRP-expressing neurons in
the arcuate nucleus of the hypothalamus potently
promotes feeding, thus defining new regulators of
AgRP neuron activity could uncover potential novel
targets for obesity treatment. Here, we demonstrate
that AgRP neurons express the purinergic receptor
6 (P2Y6), which is activated by uridine-diphosphate
(UDP). In vivo, UDP induces ERK phosphorylation
and cFos expression in AgRP neurons and promotes
action potential firing of these neurons in brain slice
recordings. Consequently, central application of
UDP promotes feeding, and this response is abro-
gated upon pharmacologic or genetic inhibition of
P2Y6 as well as upon pharmacogenetic inhibition of
AgRP neuron activity. In obese animals, hypothalam-
ic UDP content is elevated as a consequence of
increased circulating uridine concentrations. Collec-
tively, these experiments reveal a potential regulato-
ry pathway in obesity, where peripheral uridine in-
creases hypothalamic UDP concentrations, which
in turn can promote feeding via PY6-dependent acti-
vation of AgRP neurons.
INTRODUCTION
Facing the escalating burden of obesity and type 2 diabetes mel-
litus (T2DM) (Geiss et al., 2014; WHO, 2006), there is an urge to
further define the regulatory principles underlying the control of
body weight and glucose homeostasis and to define novel tar-
gets for therapeutic intervention. Research over the past de-
cades revealed the critical importance of the central nervous
system (CNS) and, more specifically, the hypothalamus in con-
trol of homeostatic processes governing energy balance and
glycemic control (Schwartz et al., 2013; Sohn et al., 2013).1404 Cell 162, 1404–1417, September 10, 2015 ª2015 Elsevier Inc.Here, particularly the arcuate nucleus of the hypothalamus
(ARH) is of critical importance to coordinate food intake and gly-
cemic control with the energy state of the organism (Sohn et al.,
2013; Varela and Horvath, 2012). The ARH contains two main
functionally antagonistic neuronal populations: the orexigenic
neurons co-expressing neuropeptide Y (NPY) and agouti-related
peptide (AgRP) and the anorexigenic neurons that produce proo-
piomelanocortin (POMC) (Sohn et al., 2013; Varela and Horvath,
2012). Thus, themelanocortin circuitry downstream of AgRP and
POMC neurons orchestrates behavioral responses such as
feeding and locomotor activity, as well as changes in peripheral
glucose metabolism in rodents and in humans (Cone, 2005; Far-
ooqi and O’Rahilly, 2008).
AgRP/NPY and POMC neurons express leptin and insulin re-
ceptors, and several studies previously highlighted the critical
importance of insulin and leptin action specifically on AgRP/
NPY and/or POMC neurons in their anorexigenic and glucoregu-
latory effects (Belgardt and Bru¨ning, 2010; Ko¨nner and Bru¨ning,
2012; Varela and Horvath, 2012; Vogt and Bru¨ning, 2013). How-
ever, while leptin and insulin are indisputably critical regulators of
AgRP/NPY and POMC neurons, the discovery that obesity and
T2DMare associatedwith the onset of neuronal leptin and insulin
resistance in these two neuronal populations limits pharmaceu-
tical interventions targeting these hormonal pathways (Fried-
man, 2004; Ko¨nner and Bru¨ning, 2012; Vogt and Bru¨ning,
2013). Thus, defining alternative signaling pathways in control
of the melanocortin circuitry will ultimately expand the panel of
putative drugs targets for the treatment of obesity and T2DM.
Among all potential new regulators of the central control of
feeding behavior and glucose homeostasis, the family of G-pro-
tein-coupled receptors (GPCRs) carries enormous therapeutic
potential since, on one hand, they are well known to regulate
virtually all core physiological functions and, on the other hand,
they are attractive targets for pharmacological intervention due
to their high-affinity binding and selectivity (Allen and Roth,
2011). Recently, Ren and coworkers discovered that Gpr17 is
expressed on AgRP neurons and that Gpr17 downregulation
secondary to AgRP-specific FoxO1 deletion is associated with
decreased body weight and food intake (Ren et al., 2012). Given
the putative role of Gpr17 in feeding regulation, we thought of
investigating whether related GPCRs could also be expressed
on hypothalamic neurons, thereby controlling their function
and associated behavioral outcomes. Gpr17 is structurally
and phylogenetically related to the purinergic receptors family
(P2), more specifically to P2Y receptors activated by uracil
nucleotides (Daniele et al., 2011). Interestingly, members of the
P2Y family, such as P2Y1 and P2Y14, have previously been
associated with homeostatic processes such as food intake
and insulin sensitivity (Burnstock et al., 2011; Kittner et al.,
2006; Xu et al., 2012). Here, we find that, among uracil nucleo-
tide-sensitive P2Y receptors with so far unknown function in
the central control of energy and glucose homeostasis, P2Y6 is
the highest expressed in the ARH. Therefore, we decided to
directly focus on the putative role of P2Y6 in energy and glucose
homeostasis. P2Y6 is a receptor for the nucleotide uridine-
diphosphate (UDP), whose synthesis in the CNS depends on
the salvage pathway, which is directly controlled by the periph-
eral supply of the precursor metabolite uridine (Cansev, 2006;
Ipata, 2011).
We demonstrate that UDP activates AgRP neurons in a P2Y6-
dependent fashion. In accordance with its stimulatory effect on
AgRP neurons, centrally administered UDP displays orexigenic
effects, which are abrogated upon pharmacologic or genetic
inhibition of P2Y6 as well as upon pharmacogenetic inhibition
of AgRP neurons. Moreover, hypothalamic UDP content is in-
creased in obesity. Our experiments thus reveal a potential reg-
ulatory pathway in obesity, where elevated uridine supply from
the periphery increases hypothalamic UDP content to activate
AgRP neurons and ultimately promote positive energy balance.
RESULTS
P2Y6 Are Expressed in Neurons of Key Hypothalamic
Feeding Regions
In order to identify potential novel GPCR-coupled regulators of
energy homeostasis, we assessed the expression of P2Y recep-
tors activated by uracil nucleotides, which have not previously
been linked to energy and glucose homeostasis in hypothalami
as well as in microdissected ARH. These analyses revealed
that, both in hypothalami and in microdissected ARH, the ex-
pression level ofP2ry6-mRNAwas ten times higher as compared
to the other studied P2Y members (Figures S1A and S1B). To
further investigate whether P2Y6 is particularly enriched in the
ARH, we next compared the expression levels of P2ry6-mRNA
in different hypothalamic regions such as the ARH, the paraven-
tricular nucleus of the hypothalamus (PVH), the ventromedial nu-
cleus of the hypothalamus (VMH), the dorsomedial nucleus of the
hypothalamus (DMH), and the lateral hypothalamic area (LHA).
The greatest mRNA expression level of P2ry6 was found in the
ARH, where it is expressedz25 to 40% higher than in other hy-
pothalamic regions (Figure 1A). Since P2Y6 has been described
as the receptor for uridine-diphosphate (UDP), we next analyzed
whether the expression of P2Y6 occurs in the same regions
where UDP is produced. A critical step in neuronal UDP
synthesis relies on phosphorylation of uridine, which is mediated
by uridine-cytidine kinases (UCK)-1 and -2 (Anderson andCBrockman, 1964). Expression analyses of Uck1 and Uck2
mRNA revealed an overall similar pattern to that of P2Y6 (Figures
1B and 1C).
Next, we aimed to verify P2Y6 expression in hypothalamic
nuclei through the analyses of GFP immunohistochemistry in
mice, which express GFP from the endogenous P2ry6 locus
(P2Y6-EGFP mice) (Bar et al., 2008). Consistent with the pattern
of P2ry6 mRNA expression, these immunohistochemical ana-
lyses revealed a very specific regional distribution of P2Y6-
dependent GFP expression most prominently in the ARH and
to a minor extent in the PVH, while the VMH, the DMH, and
LHA exhibited only a minor proportion of cells positive for GFP
expression (Figures 1D and S1C).We also compared the expres-
sion pattern of P2Y6-dependent GFP expression with that of the
endogenous P2ry6 mRNA available through the Allen Brain
Atlas, which revealed a similar distribution of P2ry6 expression
in the hypothalamus (http://mouse.brain-map.org/experiment/
show?id=1800). Collectively, these analyses revealed a predom-
inant enrichment of P2Y6 expression in the ARH.
To further investigate which cell type in the ARH expresses
P2Y6, we next performed co-immunohistochemical staining for
GFP in P2Y6-EGFP mice and for antibodies directed to either
CD11b (microglia) or GFAP (astrocytes) or using fluorescent
Nissl staining NeuroTrace (neurons). There was no overlap be-
tween cells expressing GFAP or CD11b and those expressing
GFP from the P2ry6 locus (Figure 1E). In contrast, there was a
clear overlap of immunoreactivity for P2Y6-dependent GFP
expression in the NeuroTrace-positive neurons in the ARH (Fig-
ure 1E). Taken together, these experiments clearly indicate that
the UDP receptor P2Y6 is highly expressed in neurons of
the ARH.
The P2Y6 Agonist UDP Activates Neurons in the ARH
Having identified a restricted domain of P2Y6 expression in neu-
rons of the ARH, we next investigated whether intracerebroven-
tricular (icv) application of the P2Y6 agonist UDP modulates
activation of ARH neurons. Following icv administration of either
vehicle (i.e., saline) or 30 mM UDP, quantitative assessment of
cFos immunoreactive cells revealed a 2.5-fold increase in cFos
immunoreactivity in the ARH (Figure 2A). Similarly, the VMH,
DMH, and LHA exhibited a significant increase in cFos-immuno-
reactive cells following icv UDP application (Figure S2A). In
contrast, cFos immunoreactivity in the PVH was only increased
to a minor extent (Figure S2A). Since cFos activation can
occur either directly in the respective brain area or indirectly
via trans-synaptic activation of cells located in projecting areas
of directly activated neurons, we sought to investigate the direct
effect of UDP on its P2Y6. In the periphery, UDP action on P2Y6
can lead to tyrosine phosphorylation of MAP kinases ERK-1 and
ERK-2 (pERK) (Bar et al., 2008). Using a hypothalamic cell line,
we found that, indeed, UDP activated ERK-phosphorylation
also in these cells (Figure S2B). Therefore, we used pERK as a
direct readout of UDP action on P2Y6. Quantification of pERK
immunoreactivity revealed that UDP significantly increased the
number of pERK-positive cells in the ARH (Figure 2B). Taken
together, these analyses revealed that P2Y6 are expressed on
ARH neurons and that they are functional, as UDP directly acti-
vates signaling in these neurons.ell 162, 1404–1417, September 10, 2015 ª2015 Elsevier Inc. 1405
Figure 1. P2Y6 Is Highly Expressed in Neurons of the Arcuate Nucleus
(A–C) Quantitative real-time PCR analysis of (A) pyrimidinergic receptor P2Y, G protein coupled, 6 (P2yr6) (n = 18–20 samples per region), (B) uridine-cytidine
kinase 1 (Uck1) (n = 18–20 samples per region), and (C) uridine-cytidine kinase 2 (Uck2) (n = 17–19 samples per region) mRNA expression in key microdissected
hypothalamic regions: the paraventricular nucleus of the hypothalamus (PVH), the arcuate nucleus of the hypothalamus (ARH), the ventromedial nucleus of the
hypothalamus (VMH), the dorsomedial nucleus of the hypothalamus (DMH), and the lateral hypothalamic area (LHA).
(legend continued on next page)
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UDP Activates AgRP/NPY-Expressing Neurons in
the ARH
Given the expression of the UDP receptor P2Y6 in the ARH, as
well as the clear activation of both cFos-expression and ERK
phosphorylation in the ARH in response to icv UDP application,
we next aimed to define the molecular identity of the P2Y6-ex-
pressing, UDP-responsive neurons in this region. Interestingly,
UDP-induced pERK immunoreactive cells displayed a specific
anatomical distribution mainly in the ventromedial region of the
ARH (Figure 2B). Given that the ventromedial part of the ARH
mainly contains AgRP/NPY-coexpressing neurons (Chronwall,
1985), we next directly investigated the specific effect of P2Y6/
UDP on those neurons. For this purpose, we repeated the
UDP-induced pERK experiments in mice, which express GFP
under control of the NPY promotor (NPY-GFP mice). This anal-
ysis revealed that, indeed, the number of NPY-expressing neu-
rons exhibiting pERK immunoreactivity doubled following icv
UDP application, as compared to vehicle-treated controls (Fig-
ure 2C). Similar results were found using cFos as a readout for
NPY neuron activation (Figure S2C). In contrast, UDP failed to
significantly increase pERK immunoreactivity in GFP-expressing
anorexigenic POMC neurons of POMC-GFP mice (Figure 2D).
Collectively, these experiments indicate that UDP specifically
evokes ERK phosphorylation immunoreactivity in orexigenic
AgRP/NPY neurons, but not in POMC neurons.
Based on the restricted action of UDP on AgRP/NPY neurons
in the ARH, we specifically focused on the role of UDP/P2Y6
on this neuronal population. We first investigated the expression
of P2Y6 on AgRP/NPY neurons. To this end, we performed a
co-immunohistochemistry for GFP expression on ARH sections
of P2Y6-EGFP mice together with antisera directed against
AgRP. This analysis revealed co-expression of P2Y6 and endog-
enous AgRP (Figures 3A and S3A). In addition, we performed co-
staining of endogenous P2Y6 in transgenicmice that express the
red tomato protein under control of the AgRP promoter through
Cre-loxP-mediated recombination in AgRPtdTomato mice (Figures
3B, S3B, and S3C). Using this approach, we also found that
genetically marked AgRP neurons express endogenous P2Y6
receptors.
Next, we aimed to further directly support the notion that the
P2Y6 agonist UDP can modulate the activity of AgRP-express-
ing neurons in the ARH. Therefore, we performed perforated
patch-clamp recordings from AgRPtdTomato neurons (Figures
3C–3F). Here, we also found that >60% of AgRP neurons are
sensitive to UDP (Figure 3E), as application of 3 mMUDP resulted
in an increased action potential frequency of these cells (Figures
3C–3F). In contrast, when we conducted similar recordings in
brain slices of POMC-GFP mice, we found that only a small pro-
portion of POMC neurons are responsive to UDP and that UDP
does not significantly affect POMC neuron action potential firing
on a population basis (Figures S3D and S3E). Collectively, these(D) Representative microphotographs of GFP immunostaining (P2Y6-EGFP, gre
VMH, the DMH, the LHA, and the PVH of P2Y6-EGFP mice.
(E) Representative microphotographs of ARH co-immunostaining of P2Y6-EGF
(middle row) glial fibrillary acicid protein (GFAP, astrocytes, red), and (bottom ro
Data are presented as mean ± SEM. Scale bars: D, 100 mm and E, 50 mm. V3, third
by Newman-Keuls posthoc test. See also Figure S1.
Cexperiments indicate that orexigenic AgRP/NPY-coexpressing
neurons in the ARH not only express the UDP receptor P2Y6,
but that they are also directly activated following UDP applica-
tion both in vitro and in vivo.
UDP Promotes Feeding via P2Y6-Dependent Activation
of AgRP Neurons
In light of the pivotal role of AgRP neuron activation in the
stimulation of food intake, we investigated whether UDP was
indeed capable of promoting an increase in feeding. Therefore,
control mice were icv injected with increasing doses of UDP
before the onset of the dark period, i.e., when spontaneous
feeding occurs in mice. Indeed, central application of UDP
acutely enhanced spontaneous food intake in a dose-dependent
manner (Figure 4A). Importantly, the same dose of centrally
applied UDP (30 mM), which evoked the strongest activation
of neurons in the ARH, also elicited the strongest stimulatory
effect on food intake by increasing food intake by 45%
compared to animals subjected to vehicle injection (Figures 4A
and S4A–S4C).
To directly assess whether the ability of centrally applied
UDP to activate feeding depends on AgRP neuron activation,
we investigated the effect of centrally administered UDP in
mice, which allow for pharmacogenetic inhibition of AgRP neu-
rons. To this end, we injected AgRPCre mice bilaterally into the
ARH with an AAV, which co-expresses in a Cre-dependent
manner the inhibitory DREADD channel hM4D and mCherry.
Immunostaining for m-Cherry revealed successful bilateral tar-
geting of the ARH in these mice (Figure 4B). While in Cre-nega-
tive control animals bilateral injection of the AAV and intraperi-
toneal CNO application had no effect on UDP’s ability to
increase food intake, UDP’s food intake-stimulatory effect
was completely abolished upon CNO-mediated inhibition of
AgRP neurons of AAV-injected AgRPCre mice (Figure 4C). While
AgRP neuron activity is required for UDP’s orexigenic ef-
fect, mRNA expression levels of Agrp, Npy, or Pomc are not
affected over time by icv UDP application (Figures S4D–S4F).
Taken together, these experiments clearly revealed that cen-
trally applied UDP enhances food intake and that this effect
is abolished when activation of AgRP neurons is specifically
inhibited.
To further elucidate the specific contribution of P2Y6-medi-
ated signaling in UDP-dependent activation of food intake, we
took both a pharmacological and a genetic approach. We first
compared the orexigenic effect of centrally applied UDP in either
the absence or presence of the well-characterized P2Y6 antag-
onist MRS 2578. Again, while UDP injection increased food
intake byz50% also in these independent sets of experiments,
this responsewas completely abrogated upon co-treatment with
the P2Y6 antagonist (Figure 5A). Importantly, for this experiment,
we used a dose of MRS 2578 that does not modulate food intakeen) and of corresponding nuclear counterstaining (DAPI, blue) in the ARH, the
P (P2Y6-EGFP, green) and of: (top row) integrin aM (Cd11b, microglia, red),
w) fluorescent Nissl staining (NeuroTrace, neurons, red).
ventricle. *p < 0.05 and **p < 0.01, as determined by one-way ANOVA followed
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Figure 2. UDP Triggers pERK Activation in Orexigenic AgRP Neurons, but Not in Anorexigenic POMC Neurons
(A and B) Confocal images and quantification comparison of (A) cFos- and (B) pERK-immunoreactive cells in the arcuate nucleus (ARH) of mice after intra-
cerebroventricular administration of vehicle (saline) or 30 mM UDP (ncFos = 7 versus 9; npERK = 14 versus 16).
(legend continued on next page)
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by itself (Figure 5A). To investigate whether the inhibition of UDP-
induced feeding by central administration of MRS 2578 might
stem from unspecific side effects of the antagonist, we also
tested the effect of MRS 2578 on the ability of centrally applied
ghrelin to increase feeding. Here, icv application of 2 mg ghrelin
increased feeding to a comparable extent as observed upon
UDP injection (Figure 5B). However, co-application of the P2Y6
antagonist MRS 2578 had no effect on ghrelin’s ability to in-
crease food intake (Figure 5B). These findings clearly provided
the first evidence that UDP’s ability to increase feeding is specif-
ically mediated via P2Y6-dependent signal transduction.
To further support this notion, we compared the ability of
centrally applied UDP to increase food intake in control and in
P2Y6-deficient mice (P2Y6D/D). While UDP clearly increased
feeding in control mice, it completely failed to increase food
intake in litter mates lacking functional P2Y6 expression (Fig-
ure 5C). In contrast, P2Y6-deficient mice exhibited a comparable
ability to increase food intake in response to central ghrelin appli-
cation, as compared to their litter mate controls (Figure 5D).
Collectively, both pharmacological and genetic inhibition of
P2Y6 specifically abrogate the acute orexigenic action of cen-
trally applied UDP, but not of ghrelin, clearly demonstrating
that UDP specifically engages P2Y6 signaling to increase food
intake.
Having defined that the food-intake-promoting activity of UDP
is mediated through P2Y6-dependent signaling, we aimed to
assess whether UDP’s ability to increase AgRP neuron firing de-
pends on functional P2Y6 signaling. To this end, we performed
electrophysiological recordings from genetically identified
AgRP neurons in AgRPtdTomato mice. MRS 2578 preincubation
abrogated UDP’s ability to increase action potential firing of all
but a single recorded AgRP neuron (Figures 5E and 5F). Thus,
not only UDP-induced activation of feeding, but also UDP-stim-
ulated activation of AgRP neurons critically depends on func-
tional P2Y6 signaling.
Hypothalamic UDP Concentrations Are Increased in
Obesity
Having identified a regulatory role for UDP-evoked P2Y6-depen-
dent signaling in control of AgRP neuron activity and feeding,
we assessed whether P2Y6 expression or UDP concentrations
might be altered in the hypothalamus in obesity. Therefore, we
compared the hypothalamic mRNA expression of P2ry6 in con-
trol mice and diet-induced obese animals as well as in control
mice and mice carrying a mutation in the leptin receptor gene
(db/db mice). This analysis revealed unaltered expression of
P2ry6 in the hypothalamus of diet-induced and genetically obese
animals (Figures 6A and 6B). In contrast, ultra-performance
liquid chromatography (UPLC)-based assessment of hypotha-
lamic UDP concentrations revealed a significant increase in hy-
pothalamic UDP content in both obese mouse models (Figures
6C and 6D). Moreover, hypothalamic UDP concentrations posi-
tively correlated both with body weight and markers of impaired(C and D) Confocal images and quantitative comparison of (C) NPY-GF
intracerebroventricular administration of vehicle (saline) or 30 mM UDP (nNPY
ventricle.
Data are presented as mean ± SEM. **p < 0.01, ***p < 0.001, as determined by u
Cglucose homeostasis such as fasting glycemia and HOMA-IR in
obese mice (Figures 6E and 6F). Collectively, these experiments
revealed that, under conditions of obesity, hypothalamic con-
centrations of the P2Y6 ligand UDP are increased in the absence
of alterations in P2ry6 mRNA expression.
Circulating Uridine Concentrations Are Increased in
Obesity and Can Promote Hypothalamic UDP Synthesis
Since we detected elevated hypothalamic UDP concentrations
in both diet-induced and genetically determined obesity, we
further investigated potential mechanisms underlying this phe-
nomenon. Thus, we monitored the mRNA expression of key
enzymes of UDP synthesis and conversion (Figure S5). However,
there was no consistent alteration in hypothalamic mRNA
expression for the key regulatory gene products in UDP synthe-
sis or conversion detectable in the hypothalamus of high-fat-
diet-fed or db/db mice (Figures 7A and 7B).
Neuronal UDP synthesis critically depends on the availability
of uridine, which reaches the brain via transporter-mediated
uptake (Cansev, 2006; Ipata, 2011). Therefore, we compared
the expression of known transporters for pyrimidine and py-
rimidine metabolites in the hypothalamus of control mice and
diet-induced obese animals, as well as db/db mice. However,
there was no consistent alteration in the mRNA expression of
Slc28a and Slc29a family members in diet-induced or genetically
determined obesity (Figures 7C and 7D).
In contrast, when we assessed circulating serum uridine
concentrations, there was a significant increase in serum uri-
dine concentrations in obese mice (Figure 7E). Moreover, we de-
tected a positive correlation between serum uridine concentra-
tions and hypothalamic UDP content in these animals
(Figure 7F). Collectively, these data indicate that, in obesity,
serum uridine concentrations increase and this subsequently
may lead to increased hypothalamic UDP synthesis.
To directly address whether elevation of serum uridine con-
centrations—as observed in obesity—can lead to increased
hypothalamic UDP synthesis, we next injected control ani-
mals intraperitoneally with uridine. The acute i.p. injection of
50mg/kgBW uridine resulted in a rapid increase of serum uridine
concentrations 60 min post injection and serum levels returned
to baseline concentrations 90 min after injection (Figure 7G).
This increase in circulating uridine concentrations resulted in
subsequent elevation of hypothalamic UDP content as early as
90 min after peripheral application of uridine (Figure 7H). Finally,
consistent with the notion that increased hypothalamic UDP
concentrations can enhance feeding, animals injected intraperi-
toneally with uridine increased food intake significantly 4 hr after
peripheral application of uridine (Figure 7I). Taken together,
our experiments revealed that, in obesity, circulating uridine
concentrations are increased, providing enhanced substrate
availability for hypothalamic UDP synthesis and ultimately pro-
moting feeding via UDP-induced P2Y6 signaling in the CNS
(Figure S6).P and (D) POMC-GFP expressing neurons pERK immunoreactive after
-GFP = 4 versus 5; nPOMC-GFP = 5 versus 5). Scale bar, 100 mm. V3, third
npaired Student’s t test. See also Figure S2.
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(legend on next page)
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DISCUSSION
Better defining the regulatory processes underlying the central
control of food intake and metabolism is key to the develop-
ment of novel drugs targeting the current obesity and diabetes
epidemic (Geiss et al., 2014; WHO, 2006). Here, we have
unraveled a pathway that regulates feeding behavior as we
uncover an unappreciated role for the UDP-selective P2Y6 in
control of AgRP neuron activity and their associated orexi-
genic effects. Moreover, we reveal that this UDP/P2Y6
pathway is activated in response to raising uridine supply
from the periphery of the organism, as observed in obesity,
where both circulating uridine concentrations and hypotha-
lamic UDP content are increased (Figure S6). While currently
little information is available on the physiological regulation
of circulating uridine or hypothalamic UDP concentrations in
relation to acute changes in energy state, some studies have
recently described that circulating plasma uridine concentra-
tions are increased in humans suffering from T2DM and corre-
late with the degree of insulin resistance also in rodents,
consistent with the increase of circulating uridine in db/db
mice reported here (Dudzinska et al., 2013; Hamada et al.,
2007; Hawkins et al., 1997; Urasaki et al., 2014; Yamamoto
et al., 2010). Given that AgRP neurons are not only critical
for the control of feeding, but also for control of hepatic
glucose production (Ko¨nner et al., 2007), altered uridine/
UDP-mediated control of these cells may not only contribute
to obesity development, but also to the pathogenesis of
altered glucose homeostasis. Clearly, future studies on
P2Y6-deficient mice will have to delineate the role of UDP/
P2Y6-dependent signaling in the development of obesity and
T2DM, as well as states of negative energy balance or weight
loss.
Extracellular nucleotides act as signaling molecules to
mediate a wide range of cellular and physiological responses
by acting on cell-surface purinergic receptors (P2) (Abbracchio
et al., 2009; Burnstock et al., 2011). A striking example of the
importance of purinergic signaling was the discovery that ATP
acts as a neurotransmitter regulating core functions, such as
circadian rhythm, sensory processes, and nociception, as
well as higher-order cognitive functions, including motivation,
learning, and memory (Burnstock, 2006; Burnstock et al.,
2011). Surprisingly, despite indisputable recognition of the crit-
ical importance of purine and pyrimidine signaling as a privilegedFigure 3. AgRP Neurons Express P2Y6 Whose Activation by UDP Dire
(A and B) Representative microphotographs of co-immunostaining of (A) P2Y6-E
and AgRPtdTomato (AgRPtdTomato, red) in the arcuate nucleus of the hypothalamus
(C) UDP effect on a single AgRP neuron. Action potential frequency (black line
and traces in higher resolution (bottom) of an AgRP neuron increasing firing freq
indicates ± 33 SD and the dotted line the respective mean of the control calculat
calculate means and SD for control and effect, respectively. The increase in act
neuron as a responsive neuron.
(D) Recorded neuron, identified by antibody staining against tdTomato (red) and
(E) Overall responsiveness to 3 mM UDP of the recorded AgRP neuron populatio
(F) Quantification of action potential (AP) frequency (n = 11, responsive and no
significant increase in AP frequency; open circles are non-responsive neurons. A
Scale bars: A andB, 50mmandD, 40mmand10mmin themagnifications, respectiv
the Tukey method (mean, ‘‘+’’; median, horizontal line). **p < 0.01, as determined b
Croute for cell-to-cell communication in numerous physiological
processes, very little is known about the role of purinergic
signaling in the CNS-dependent control of energy and glucose
homeostasis. Within the several members of the P2 family, we
particularly focused on the P2 receptors activated by uracil nu-
cleodites and derived sugar nucleotides based on their structural
and phylogenetic similarity to Gpr17 (Daniele et al., 2011), which
was recently identified as a novel FoxO1-dependent regulator
of AgRP neuron activity (Ren et al., 2012). Among the uracil nu-
cleotides and derivates-binding members with unknown func-
tion in the CNS-dependent control of metabolism, P2Y6 stands
out by its high expression levels in the ARH. As opposed to the
hippocampus, where P2Y6 colocalizes with activated microglia
(Koizumi et al., 2007), in the ARH of lean mice, we identify
P2Y6 as being specifically expressed in neurons, providing evi-
dence for a region-dependent, cell-type-specific expression
pattern of P2Y6 in the CNS. Guided by the microglial expression
of P2Y6, previous studies had mostly focused on the microglial
role of P2Y6, where P2Y6 signaling was demonstrated to acti-
vate microglia and to promote phagocytosis (Koizumi et al.,
2007). Here, we show that, in contrast, P2Y6 directly activates
AgRP neurons in the ARH to potently promote feeding, while it
only has minor effects on the activation of anorexigenic POMC
neurons. This notion is consistent with the robust activation of
feeding upon optogenetic or pharmacogenetic activation of
AgRP neurons (Aponte et al., 2011; Krashes et al., 2011) and their
previously defined crucial role for the maintenance of feeding, as
evidenced by toxin-mediated ablation of these cells in adult mice
(Gropp et al., 2005; Luquet et al., 2005).
Besides our demonstration that AgRP neurons express P2Y6
and that AgRP neuron activity is required to promote feeding in
response to centrally applied UDP, we reveal that UDP triggers
pERK phosphorylation and increased action potential firing in
a substantial proportion of AgRP neurons. Excitatory effects of
UDP have previously been described in cultured sympathetic
neurons in which UDP-induced depolarization evoked noradren-
aline release (No¨renberg et al., 2000; von Ku¨gelgen et al., 1997).
Accordingly, similar mechanisms may occur in AgRP neurons,
where UDP induces increased firing of action potentials to sub-
sequently releaseGABA and the characteristic orexigenic neuro-
peptides produced by these cells, i.e., NPY and AgRP. Recently,
Krashes and coworkers described the differential functions of
neuromediators released by AgRP neurons in controlling tempo-
rally distinct phases of eating behavior. Here, GABA and NPY arectly Increases Firing Rate
GFP (P2Y6-EGFP, green) and of AgRP (AgRP, red) and (B) P2Y6 (P2Y6, green)
(ARH).
) and respective rate histogram (30 s bins, top), original recording (middle),
uency in response to the application of 3 mM UDP. Shaded gray background
ed from 12 bins of 30 s each. Arrows beneath the bins indicate the bins used to
ion potential frequency is larger than 3 3 SD of the control, thus defining this
a biocytin fill of the recorded neuron (green).
n (n = 11 in total: 4 non-responsive neurons versus 7 responsive).
n-responsive pooled). Gray circles mark single recordings responding with a
ll recordings have been conducted in synaptically isolated neurons.
ely. V3, third ventricle. Data are representedasboxplots generated according to
y paired Student’s t test, including all recorded 11 neurons. See also Figure S3.
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Figure 4. Central UDP Dose Dependently Increases Food Intake,
and Its Orexigenic Effects Require AgRP Neuron Activity
(A) 2 hr food intakemeasurement (depicted as food intake to body weight) after
intracereborventricular (icv) administration of increasing doses of UDP (1 mM,
10 mM, and 30 mM) or vehicle (saline) (n = 26 versus 13 versus 11 versus 14).
(B) Representative microphotographs of mCherry immunostainng in control
and AgRPCre mice injected bilaterally in the arcuate nucleus (ARH) with Cre-
dependent rAAV-hSyn-DIO-hM4D(Gi)-mCherry (mCherry, red; DAPI counter-
staining, blue). Scale bar, 100 mm. V3, third ventricle.
(C) 2 hr food intake measurement in virus-injected AgRPCre mice or control
wild-type litter mates. Mice received CNO injections (0.3 mg/kgBW) 15 min
prior to icv administration of 30 mM UDP or vehicle (saline) (n = 6 versus 8
versus 5 versus 5).
Data are presented as mean ± SEM. **p < 0.01, ***p < 0.001, as compared to
vehicle as determined by one-way ANOVA followed by Newman-Keuls post-
hoc test (A) or unpaired Student’s t test (C). See also Figure S4.
1412 Cell 162, 1404–1417, September 10, 2015 ª2015 Elsevier Inc.promoting food intake in the short term, whereas AgRP is
responsible for the long-term stimulation of eating (Krashes
et al., 2013). This study and the specific short-term effect of
UDP on food intake suggest that the orexigenic effect of UDP
may depend on GABA- and/or NPY-mediated signals originating
from AgRP/NPY co-expressing neurons rather than on AgRP.
This notion is further substantiated through the notion that
UDP acutely promotes feeding without obvious changes in the
transcription of Agrp and Npy mRNAs. However, this assump-
tion will have to be directly addressed in future studies.
In accordance with the ability of UDP to increase Ca2+ levels
in neurons, it is well described that activation of P2Y6 by UDP
leads to activation of various Ca2+-dependent signaling path-
ways, including IP3 accumulation and an increase in cyto-
plasmic free Ca2+ from intracellular Ca2+ stores (Brunschweiger
and Mu¨ller, 2006). In addition, P2Y6 shares convergent
signaling pathways with the receptor for ghrelin, which also ex-
erts its orexigenic effects predominantly through the activation
of AgRP neurons (Tscho¨p et al., 2000 and for review, Andrews,
2011). First, as for ghrelin (Steculorum et al., 2015), we found
that UDP activates MAPK/ERK signaling in AgRP neurons
both in vitro and in vivo. Second, several peripheral effects of
P2Y6 directly rely on AMPK activation (Balasubramanian
et al., 2013, 2014), and AMPK is a critical element in mediating
the orexigenic effects of ghrelin through activation of AgRP/
NPY neurons (Andrews, 2011). Moreover, consistent with a crit-
ical role for AMPK regulation in AgRP neuron activity, AgRP
cell-specific AMPK-deficient mice develop a lean phenotype
(Claret et al., 2007), further supporting the idea that the orexi-
genic effect of UDP may indeed be associated with a P2Y6-
dependent activation of AMPK in these cells. Clearly, the
downstream signaling pathway(s) of P2Y6 in AgRP/NPY neu-
rons will have to be further characterized in detail.
Another key aspect of the results presented here is our
demonstration that the orexigenic effect of UDP completely re-
lies on functional P2Y6 signaling, as evidenced by pharmaco-
logic and genetic inhibition of P2Y6 signaling. This rules out the
possibility that UDP is used as a precursor metabolite by mem-
brane-bound or soluble enzymes since P2Y6 is the exclusive re-
ceptor for UDP and not for its metabolites, such as UDP glucose
or UTP, which, respectively, act through P2Y14 and P2Y2/P2Y4
(Brunschweiger and Mu¨ller, 2006). This point is of critical impor-
tance, as it was previously shown that UDP glucose, when co-in-
jected icv with leukotrienes, increases food intake (Ren et al.,
2012). Our experiments thus clearly identify specifically P2Y6
as a target for inhibiting the food-intake-promoting actions of
increased hypothalamic UDP in obesity.
In addition to expression of P2Y6, we reveal that critical com-
ponents of enzymatic machinery for the biosynthesis of UDP—
UCK-1 and -2, which catalyze the phosphorylation of uridine to
UMP and represent the rate-limiting step for the UDP production
(Anderson and Brockman, 1964)—are highly expressed in the
ARH. The exact nature of UDP-synthesizing and -releasing cells,
as well as a potential autocrine versus paracrine mode of UDP
action on P2Y6 expressed on AgRP neurons, still remains to
be investigated. CNS UDP biosynthesis is critically dependent
on uridine supply and therefore directly relies on uridine uptake
from the periphery (Cansev, 2006; Ipata, 2011). Irrespective of
Figure 5. UDP Promotes Feeding and Activates AgRP Neurons via P2Y6-Dependent Signaling
(A–D) 2 hr food intakemeasurement after intracerebroventricular (icv) administration of (A) vehicle (0.1%DMSO), 1 mMof the P2Y6-specific antagonist MRS 2578,
30 mM UDP or co-icv of 30 mM UDP, and 1 mM MRS 2578 (n = 10 versus 11 versus 14 versus 12) or (B) vehicle (0.1% DMSO), 1 mM MRS 2578, 2 mg ghrelin or
co-icv of 2 mg ghrelin, and 1 mM MRS 2578 (n = 13 versus 13 versus 14 versus 14). 2 hr food intake measurement after icv administration of (C) vehicle (saline)
or 30 mM UDP or (D) vehicle (saline) or 2 mg ghrelin in P2Y6-deficient mice (P2Y6D/D) or control littermates (nC = 10 versus 6 versus 9 versus 6, nD = 9 versus 9
versus 5 versus 6).
(E) Original traces showing the action potential firing during the application of MRS 2578 and during the application of 3 mM UDP in the presence of MRS 2578.
(F) Quantification of action potential frequency (AP) (n = 12). One neuron significantly increased (black circle) and two decreased (gray circles) action potential
frequency upon application of 3 mM UDP in the presence of MRS 2578.
Data are presented as mean ± SEM. *p < 0.05 (A–D) and as boxplots generated according to the Tukey method (mean, ‘‘+’’; median, horizontal line) (F). *p < 0.05,
**p < 0.01, ***p < 0.001, as compared to vehicle or control as determined by one-way ANOVA followed by Newman-Keuls posthoc test (A, B, F) or unpaired
Student’s t test (C and D).
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Figure 6. Hypothalamic UDP Content Is Increased in Dietary and Genetically Obese Mice
(A and B) Quantitative real-time PCR analysis ofpyrimidinergic receptor P2Y,Gprotein coupled, 6 (P2yr6) in hypothalamus of (A) diet-induced obese animals fed a
high-fat diet (HFD) or control animals receiving a normal chow diet (NCD) (n = 7 versus 8) and (B) db/db and their control littermates (n = 5 versus 7).
(C–F) Hypothalamic contents of (C) HFD versus NCD mice (n = 10 versus 9) and (D) in db/db and control mice (n = 7 versus 7). Correlation of hypothalamic UDP
and (E) body weight, (F) fasting glycemia, and (G) the homeostatic model assessment index of insulin resistance (HOMA-IR) in NCD and HFD mice (n = 18)
(r, Pearson’s r).
Data are presented as mean ± SEM. **p < 0.01, ***p < 0.001, as determined by unpaired Student’s t test (A–D) or Pearson’s correlation (E and F). See also
Figure S5.whether UCK-1 and UCK-2 expression in the ARH are restricted
to neurons (autocrine regulation) or other cell types to promote
paracrine UDP/P2Y6 signaling in AgRP neurons, our results
clearly show that increased hypothalamic UDP concentrations,
as observed in obese mice, and the hyperphagia secondary to
elevated central UDP can be mimicked by peripheral application
of uridine. Notably, insulin resistance in humans correlates with
increased circulating uridine concentrations (Dudzinska et al.,
2013; Hamada et al., 2007). While the predominant source of uri-
dine in lean subjects is the liver (Dobolyi et al., 2011), future
studies will have to unravel the mechanisms and tissues respon-
sible for increased uridine synthesis in metabolic disorders.
In summary, the present study identifies the UDP/P2Y6 axis as
a regulator of AgRP neuron activity and feeding behavior. This of-
fers the unique opportunity to pursue agonists and antagonists
for this GPCR as targets for the treatment of diseases associated
with negative or positive energy balance.
EXPERIMENTAL PROCEDURES
Animal Care
All animal procedures were conducted in compliance with protocols approved
by local government authorities (Bezirksregierung Ko¨ln, Cologne, Germany)
and were in accordance with National Institutes of Health guidelines. Unless
otherwise stated, animals were fed normal chow diet. Diet-induced obese
mice were fed a high-fat diet containing 26.2% carbohydrates, 26.3% protein,
and 34.9% fat (60%of calories from fat) or corresponding normal chow control1414 Cell 162, 1404–1417, September 10, 2015 ª2015 Elsevier Inc.diet. C57Bl/6N were purchased from Charles Rivers. db/db mice and their
control litter mates were purchased from The Jackson Laboratories. All exper-
iments have been performed in adult mice.
Genetic Mouse Models
All mice used in this study were previously published and have been
described in the respective paper: P2Y6-EGFP and P2Y6-deficient mice
(Bar et al., 2008), NPY-GFP mice (B6.FVB-Tg(Npy-hrGFP)1Lowl/J) (van den
Pol et al., 2009), POMC-GFP mice (C57BL/6J-Tg(Pomc-EGFP)1Low/J)
(Cowley et al., 2001), AgRP-IRES-Cre mice (AgRPCre) (Tong et al., 2008),
and tdTomato reporter mice (B6;129S6-Gt(ROSA) 26Sortm9(CAG-tdTomato)Hze/J)
(Madisen et al., 2010).
Food Intake Measurement
For all food intake studies, mice received administration of the compound prior
to the onset of the dark phase, and food intake measurement was performed
during the dark phase using chow diet.
Intracerebroventricular Injections
Intracerebroventricular (icv) cannulations were performed as described else-
where (Klo¨ckener et al., 2011). Mice received icv administration of 2 ml of
each coumpounds.
AAVs Stereotaxic Injections and CNO Administration
Bilateral injections of AAVs into the ARH were performed as described else-
where (Betley et al., 2013). rAAV5/hsyn-DIO-hM4D(Gi)-mCherry was obtained
from the UNC Gene Therapy Vector Core. Animals received intraperitoneal in-
jections of clozapine N-oxide (CNO, 0.3 mg/kgBW; Sigma) 15 min prior to icv
administration of UDP, as described above.
Figure 7. Hypothalamic UDP Is Increased in Obesity as a Consequence of Elevated Peripheral Uridine Supply
(A and B) Quantitative real-time PCR analysis ofmRNA expression levels of enzymes involved in UDP synthesis and conversion in (A) diet-induced obesemice fed
a high-fat diet (HFD) or a normal chow diet (NCD) (n = 5 versus 5) and (B) in db/db and their control litter mates (n = 5 versus 6).
(C and D) mRNA expression levels of transporters of uridine and uridine-associated nucleotides in (C) HFD and NCD mice (n = 8 versus 8) and in (D) db/db and
their control litter mates (n = 5 versus 7).
(legend continued on next page)
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Intraperitoneal Administration of Uridine
12-week-old C57bl6/N male mice received 50 mg/kgBW of uridine (i.p.;
10 ml/g; Sigma) or vehicle (saline).
Ultra-Performance Liquid Chromatography
See the Supplemental Experimental Procedures for additional details.
Immunohistochemistry
Mice were perfused transcardially with 4% paraformaldehyde, and brains
were processed as descrided previously (Steculorum et al., 2015). References
and dilution used for each antibody are included in the Supplemental Experi-
mental Procedures. Pictures were acquired using a confocal Leica TCS SP-
8-X microscope equipped with a 203 objective.
Electrophysiology
Perforated patch recordings were performed on brain slices fromAgRPtdTomato
or POMC-GFP mice. For detailed information, see the Supplemental Experi-
mental Procedures.
GeneExpressionAnalysis, Cell Culture,WesternBlot, andAnalytical
Procedures
For basic proccedures, see the Supplemental Experimental Procedures.
Statistics
All values were expressed as the means ± SEM. Statistical analyses were con-
ducted using GraphPad PRISM (version 5.0a). Data sets with only two inde-
pendent groups were analyzed for statistical significance using unpaired
two-tailed Student’s t test. Data sets comparing food intake in the same animal
subjected to two different treatments were analyzed for statistical significance
using paired two-tailed Student’s t test. Data sets with more than two groups
were analyzed using one-way analysis of variance (ANOVA) followed by New-
man-Keuls posthoc test. For correlation analysis, the Pearson product-
moment correlation (Pearson’s r) was used and reported in the corresponding
figure. All p values below 0.05 were considered significant. *p < 0.05, **p <
0.01, and ***p < 0.001.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and six figures and can be found with this article online at http://dx.doi.org/
10.1016/j.cell.2015.08.032.
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